葡萄糖依赖性降糖机制 ppt课件培训讲学.pptVIP

* * 而且，加用西格列汀组，体重降低( 相比基线 -1.5公斤) ，而加用磺脲组体重增加（相比基线 +1.1公斤）。 Notes: H.SA present Reference 1. Nauck MA, Meininger G, Sheng D, et al, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205. R.1/Nauck, p200-Par.2- L1-6 R.1/Nauck, p200-Par.1-L1 R.1/Nauck, p200-Par.2-L1 R.1/Nauck, p200-Par.2-L1 R.1/Nauck, p202-Par.Last-L1 R.1/Nauck, p194-Results-L4 R.1/Nauck,p202-F.4 R.1/Nauck, p200-Par.1-L1 p200-Par.2-L1 R.1/Nauck, p202-T.3 R.1/Nauck, p194-Results-L4 R.1/Nauck, p197-Par.2-L1 * * 加用捷诺维组， 低血糖发生率显著低于磺脲（格列吡嗪），P0.001 。 Notes: H.SA present Reference 1. Nauck MA, Meininger G, Sheng D, et al, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205. R.1/Nauck, p200-Par.2- L1-6 R.1/Nauck, p200-Par.1-L1 R.1/Nauck, p200-Par.2-L1 R.1/Nauck, p200-Par.2-L1 R.1/Nauck, p202-Par.Last-L1 R.1/Nauck, p194-Results-L4 R.1/Nauck,p202-F.4 R.1/Nauck, p200-Par.1-L1 p200-Par.2-L1 R.1/Nauck, p202-T.3 R.1/Nauck, p194-Results-L4 R.1/Nauck, p197-Par.2-L1 * Addition of Sitagliptin or Glimepiride in Patients Inadequately Controlled on Metformin: Study Design This was a multinational, double-blind, randomized, parallel-group study, which included screening period of up to 2 weeks, a 2-week placebo run-in period, and a 30-week, double-blind treatment period.1 Patients who met all enrollment criteria entered a 2-week, single-blind placebo run-in period. Patients who continued to meet the study enrollment criteria were randomized to treatment with sitaglipt